Kevin R. Lind
2016 - Arena Pharmaceuticals
In 2016, Kevin R. Lind earned a total compensation of $1.3M as Executive Vice President, Chief Financial Officer at Arena Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $96,438 |
|---|---|
| Option Awards | $939,680 |
| Salary | $218,205 |
| Other | $27,690 |
| Total | $1,282,013 |
Lind received $939.7K in option awards, accounting for 73% of the total pay in 2016.
Lind also received $96.4K in non-equity incentive plan, $218.2K in salary and $27.7K in other compensation.
Rankings
In 2016, Kevin R. Lind's compensation ranked 7,038th out of 14,075 executives tracked by ExecPay. In other words, Lind earned more than 50.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,038 out of 14,075 | 50th |
Division Manufacturing | 2,647 out of 5,486 | 52nd |
Major group Chemicals And Allied Products | 863 out of 1,900 | 55th |
Industry group Drugs | 664 out of 1,543 | 57th |
Industry Pharmaceutical Preparations | 527 out of 1,173 | 55th |
Source: SEC filing on April 28, 2017.
Lind's colleagues
We found six more compensation records of executives who worked with Kevin R. Lind at Arena Pharmaceuticals in 2016.
2016
Amit Munshi
Arena Pharmaceuticals
Chief Executive Officer
2016
Dominic Behan
Arena Pharmaceuticals
Chief Scientific Officer
2016
Steven Spector
Arena Pharmaceuticals
General Counsel
2016
Craig Audet
Arena Pharmaceuticals
Former Senior Vice President, Operations and Head of Global Regulatory Affairs
2016
Vincent Aurentz
Arena Pharmaceuticals
Executive Vice President and Chief Business Officer
2016
Harry Hixson
Arena Pharmaceuticals